• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Risk of dementia increased with gabapentin prescription in back pain patients

byPaary BalakumarandAlex Chan
July 17, 2025
in Chronic Disease, Neurology, Rheumatology
Reading Time: 2 mins read
Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Share on FacebookShare on Twitter

1. Gabapentin use was associated with a 29% increased risk of dementia and 85% increased risk of mild cognitive impairment (MCI) in chronic low back pain patients.

2. Non-elderly adults (18–64 years) had over twice the risk of dementia and MCI with gabapentin use compared to non-users.

3. The risk of cognitive decline increased with higher frequency of gabapentin prescriptions.

Evidence Rating Level: 2 (Good) 

This large retrospective cohort study investigated the association between gabapentin use and the development of dementia and mild cognitive impairment (MCI) in adults with chronic low back pain. Using deidentified data from the TriNetX national database spanning 2004 to 2024, the authors identified over 1.4 million eligible patients, ultimately including 26,416 gabapentin users and an equal number of matched controls after propensity score matching for demographics, comorbidities, and pain medications. Patients prescribed gabapentin six or more times after diagnosis were found to have significantly higher risks of both dementia (RR 1.29; 95% CI 1.18–1.40) and MCI (RR 1.85; 95% CI 1.63–2.10) within 10 years. The effect was more pronounced in non-elderly adults (18–64 years), with risk ratios exceeding 2.0, particularly in the 35–64 age group. A dose-response relationship was observed: those with 12 or more prescriptions had a higher incidence of both dementia and MCI than those with 3–11 prescriptions. The study concludes that gabapentin use in chronic low back pain is associated with increased risk of neurocognitive decline, and clinicians should be vigilant in monitoring long-term cognitive outcomes, especially in younger patients and those requiring prolonged therapy.

Click to read the study in RAPM

RELATED REPORTS

Dementia diagnosis underreporting is common and associated with reduced care engagement

Older married couples demonstrate domain-specific cognitive concordance 

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: chronic paincognitive neurologydementiageriatric medicineneurology
Previous Post

New-generation antiseizure medications are better tolerated for patients with epilepsy

Next Post

MLC901 may be effective in treatment of post-concussion symptoms in phase III study

RelatedReports

Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Chronic Disease

Dementia diagnosis underreporting is common and associated with reduced care engagement

August 29, 2026
Neurology

Older married couples demonstrate domain-specific cognitive concordance 

August 28, 2026
Chronic Disease

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

August 27, 2026
Chronic Disease

Brain-predicted age difference may reliably predict dementia progression

August 19, 2026
Next Post
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

MLC901 may be effective in treatment of post-concussion symptoms in phase III study

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

Predictors and outcomes associated with prolonged hospital length of stay in intracerebral hemorrhage

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.